Samarth Kulkarni

258 posts

Samarth Kulkarni banner
Samarth Kulkarni

Samarth Kulkarni

@CrisprSam

CEO and Chairman at CRISPR Therapeutics @CRISPRTX, which is pioneering a new era of gene-based medicines. Tweets are my own.

Boston, MA Tham gia Ekim 2015
284 Đang theo dõi4.7K Người theo dõi
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
Today we shared an update on zugo-cel (formerly CTX112) - best-in-class allogeneic CD19 CART! The data reflect encouraging progress across autoimmune disease and hematologic malignancies and support the continued advancement of zugo-cel across multiple disease settings. @CRISPRTX
CRISPR Therapeutics@CRISPRTX

Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. Learn more here: bit.ly/4asQ0ub

English
6
5
33
5.3K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
@VertexPharma and @CRISPRTX new data in children ages 5-11 with SCD or TDT were presented today at #ASH25, opening up the possibility of treating these conditions earlier in life.
English
0
4
32
2.1K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
#AHA25 and @NEJM data for CTX310 by @ProfSNicholls . A single in vivo administration safely and durably lowered ANGPTL3, reducing triglycerides and LDL, progress toward applying gene editing to more common diseases. @CRISPRTX
Samarth Kulkarni tweet media
English
6
8
44
4K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
Pleased that the FDA has included CASGEVY for patients with SCD and TDT in the CNPV pilot program, recognizing its potential clinical benefit and the importance of early intervention to help change the course of these diseases. @CRISPRTX $crsp
English
4
1
32
2.4K
Samarth Kulkarni đã retweet
Cathie Wood
Cathie Wood@CathieDWood·
Thank you, @Shea_ARK, for surfacing the potential value of one of the most important biology breakthroughs of our time: CRISPR gene editing. Many analysts seem to think that one-time cures will not be a good business, @ARK Invest begs to differ! $CRSP, $NTLA, $BEAM, $PRME
ARK Invest@ARKInvest

Cardiovascular disease is the world’s leading killer. With CRISPR-based therapies targeting lipid metabolism genes, a one-time treatment could reshape prevention and open a ~$2.8T market. Read @Shea_ARK's analysis in her first ARK research paper. ark-invest.com/articles/analy…

English
75
49
415
204.1K
Samarth Kulkarni đã retweet
BowTiedBiotech 🧪🔬🧬
BowTiedBiotech 🧪🔬🧬@BowTiedBiotech·
👀 shot > pill? 💉 > 💊 at a certain point @bioinvestor24 cites an $ABBV survey that shows psoriasis pts prefer a q3m injection over a daily pill. Analysts often assume “oral = convenient” for $KYMR in AD vs $APGE q3m shot. Reality is efficacy + freedom from daily dosing often trumps pill convenience. At a certain point efficacy is NOT perceived as equal, where that standard deviation lies varies, but end of day patients want what works, not what’s easy.
BowTiedBiotech 🧪🔬🧬 tweet media
Bioinvestor24@bioinvestor24

$ABBV management just quoted a survey that psoriasis pts prefer q 3 months injections iver daily oral pills. Beyond stat6 efficacy , why some non medical analysts automatically presume AD pill potentially from $KYMR is more convenient that q3 months shot such as from $APGE ?

English
5
3
26
10.6K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
Thank you! It’s a reflection of all the employees who are dedicated to the cause of bringing cures to patients!
Yair Einhorn@yaireinhorn

Congrats to @CrisprSam - the CEO of @CRISPRTX on being part of the TIME100’s Health list - honoring the 100 most influential people in health today. $CRSP is the first-ever company to receive an FDA approval for its Gene Editing treatment - CASGEVY. A well-deserved recognition!

English
14
1
34
4.2K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
We are excited to announce our collaboration with Sirius Tx. This strategic partnership expands our therapeutic toolkit & broadens our cardiovascular portfolio. We look forward to working closely with the Sirius team to advance this exciting asset
CRISPR Therapeutics@CRISPRTX

Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. bit.ly/4kjPEaS

English
7
2
38
3.7K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
Proud to share our latest business updates and positive top-line results from our Phase 1 clinical trial of CTX310 targeting ANGPTL3. Congratulations to our team and all who contributed to this milestone! @CRISPRTX
English
7
4
64
5.5K
Samarth Kulkarni đã retweet
John Maraganore 🇺🇸🇬🇷🇺🇦
John Maraganore 🇺🇸🇬🇷🇺🇦@JMaraganore·
U.S. leadership in biotech is a national security, economic, and public health imperative. With the attack on science and universities, instability at FDA, & weakening of the capital markets, we are at grave risk of ceding this leadership to China. This must not happen!
Biotechnology Innovation Organization@IAmBiotech

The U.S. has long led the world in biotech—driving innovation, saving lives, and fueling our economy and national security. But that leadership is now at risk. @biotech_gov report makes it clear: without bold action, we risk falling behind. Read more: bio.org/press-release/…

English
7
13
78
8.9K
Samarth Kulkarni đã retweet
Hassan
Hassan@HassanAesthetic·
@olagherej interview and how CRISPR can cure patients. We also discuss the other challenges in this space. youtu.be/8ietzVwwqM4?si…
YouTube video
YouTube
English
1
1
7
2.5K
Samarth Kulkarni đã retweet
CRISPR Therapeutics
CRISPR Therapeutics@CRISPRTX·
We are pleased to invite Briggs Morrison, M.D., to join our Board of Directors. His extensive experience in the pharmaceutical industry and expertise in clinical development will be invaluable as we continue advancing our platform and pipeline. Learn more: bit.ly/420Fhmf
CRISPR Therapeutics tweet media
English
4
8
61
5K
Samarth Kulkarni
Samarth Kulkarni@CrisprSam·
@UrnovFyodor @CrisprGlenn @NPR @robsteinnews @igisci @UCBerkeley Thx for your work Fyodor. Two important but separate notions here. How to enable more rare indications once platform is validated (switch guides!). But also, within the same disease how do we continue to improve the components (sharpen razor blades e.g. make guides more potent).
English
3
1
16
780

Khám phá

@CRISPRTX @VertexPharma @NEJM @ProfSNicholls @Nimish1316 @Shea_ARK @ark @bioinvestor24